Abiopharma

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Natera - Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair

Statement on new EU choline chloride anti-dumping measures

Mckesson Corporation Announces Third Quarter Fiscal 2026 Earnings Release Date

Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

Innovative Eyewear, Inc. Announces Participation in Key Industry Events in Q1 2026

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study